Cargando…
Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination
Vaccination with mRNA vaccines against coronavirus disease 2019 (COVID-19) has been associated with a risk of developing myocarditis and pericarditis, with an estimated standardized incidence ratio of myocarditis being 5.34 (95% CI, 4.48 to 6.40) as compared to the expected incidence based on histor...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024648/ https://www.ncbi.nlm.nih.gov/pubmed/35455324 http://dx.doi.org/10.3390/vaccines10040575 |
_version_ | 1784690654049206272 |
---|---|
author | Mengesha, Bethlehem Asenov, Asen G. Hirsh-Raccah, Bruria Amir, Offer Pappo, Orit Asleh, Rabea |
author_facet | Mengesha, Bethlehem Asenov, Asen G. Hirsh-Raccah, Bruria Amir, Offer Pappo, Orit Asleh, Rabea |
author_sort | Mengesha, Bethlehem |
collection | PubMed |
description | Vaccination with mRNA vaccines against coronavirus disease 2019 (COVID-19) has been associated with a risk of developing myocarditis and pericarditis, with an estimated standardized incidence ratio of myocarditis being 5.34 (95% CI, 4.48 to 6.40) as compared to the expected incidence based on historical data according to a large national study in Israel. Most cases of myocarditis in vaccine recipients occur in young males, particularly following the second dose, and the presentation is usually mild. Recently, the third (booster) dose has been shown to reduce confirmed infections and severe illness even against common variants of the virus. In Israel, over 4.4 million citizens (more than 45% of the population) have been vaccinated with the third dose of Pfizer-BioNTech vaccine BNT162b2. Herein, we report the first case of a histologically confirmed severe myocarditis following the third dose of BNT162b2 COVID-19 vaccine. |
format | Online Article Text |
id | pubmed-9024648 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90246482022-04-23 Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination Mengesha, Bethlehem Asenov, Asen G. Hirsh-Raccah, Bruria Amir, Offer Pappo, Orit Asleh, Rabea Vaccines (Basel) Case Report Vaccination with mRNA vaccines against coronavirus disease 2019 (COVID-19) has been associated with a risk of developing myocarditis and pericarditis, with an estimated standardized incidence ratio of myocarditis being 5.34 (95% CI, 4.48 to 6.40) as compared to the expected incidence based on historical data according to a large national study in Israel. Most cases of myocarditis in vaccine recipients occur in young males, particularly following the second dose, and the presentation is usually mild. Recently, the third (booster) dose has been shown to reduce confirmed infections and severe illness even against common variants of the virus. In Israel, over 4.4 million citizens (more than 45% of the population) have been vaccinated with the third dose of Pfizer-BioNTech vaccine BNT162b2. Herein, we report the first case of a histologically confirmed severe myocarditis following the third dose of BNT162b2 COVID-19 vaccine. MDPI 2022-04-08 /pmc/articles/PMC9024648/ /pubmed/35455324 http://dx.doi.org/10.3390/vaccines10040575 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Mengesha, Bethlehem Asenov, Asen G. Hirsh-Raccah, Bruria Amir, Offer Pappo, Orit Asleh, Rabea Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination |
title | Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination |
title_full | Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination |
title_fullStr | Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination |
title_full_unstemmed | Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination |
title_short | Severe Acute Myocarditis after the Third (Booster) Dose of mRNA COVID-19 Vaccination |
title_sort | severe acute myocarditis after the third (booster) dose of mrna covid-19 vaccination |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024648/ https://www.ncbi.nlm.nih.gov/pubmed/35455324 http://dx.doi.org/10.3390/vaccines10040575 |
work_keys_str_mv | AT mengeshabethlehem severeacutemyocarditisafterthethirdboosterdoseofmrnacovid19vaccination AT asenovaseng severeacutemyocarditisafterthethirdboosterdoseofmrnacovid19vaccination AT hirshraccahbruria severeacutemyocarditisafterthethirdboosterdoseofmrnacovid19vaccination AT amiroffer severeacutemyocarditisafterthethirdboosterdoseofmrnacovid19vaccination AT pappoorit severeacutemyocarditisafterthethirdboosterdoseofmrnacovid19vaccination AT aslehrabea severeacutemyocarditisafterthethirdboosterdoseofmrnacovid19vaccination |